Koyfin Home > Directory > Health Care > Revance Therapeutics > Preferred Equity

Revance Therapeutics Preferred Equity Chart (RVNC)

Revance Therapeutics annual/quarterly Preferred Equity from 2012 to 2013.
  • Revance Therapeutics Preferred Equity for the quarter ending December 12, 2013 was $125m a 23.40% increase of 29m year over year
  • Revance Therapeutics Preferred Equity for the last 12 months ending December 12, 2013 was $125m a 23.40% increase of 29m year over year
  • Revance Therapeutics Annual Preferred Equity for 2013 was $125m a 23.50% increase of 29m from 2012
  • Revance Therapeutics Annual Preferred Equity for 2012 was $96m a -0.13% decrease of 0m from 2011
  • Revance Therapeutics Annual Preferred Equity for 2011 was $96m
Other Balance Sheet Metrics:
  • Revance Therapeutics Total Assets for the quarter ending September 09, 2018 was $233m a -26.88% decrease of -63m year over year
  • Revance Therapeutics Other Liabilities for the quarter ending September 09, 2018 was $19m a 68.91% increase of 13m year over year
  • Revance Therapeutics Total Equity for the quarter ending September 09, 2018 was $182m a -47.64% decrease of -87m year over year
View Chart On Koyfin

Quarterly RVNC Preferred Equity Data

12/2013$125m
03/2013$118m
12/2012$96m
03/2012$96m

Annual RVNC Preferred Equity Data

2013$125m
2012$96m
2011$96m